
1. malar j. 2019 dec 16;18(1):424. doi: 10.1186/s12936-019-3015-4.

monitoring efficacy, tolerability safety artemether-lumefantrine and
artesunate-amodiaquine treatment uncomplicated plasmodium falciparum
malaria lambaréné, gabon: open-label clinical trial.

adegbite br(1), edoa jr(1), honkpehedji yj(1)(2), zinsou fj(1)(2), dejon-agobe
jc(1)(3), mbong-ngwese m(1), lotola-mougueni f(1), koehne e(1)(4), lalremruata
a(1)(4), kreidenweiss a(1)(4), nguyen tt(4)(5), kun j(4), agnandji st(1)(4), lell
b(1)(6), safiou ar(7), obone atome fa(8), mombo-ngoma g(1)(4)(9)(10), ramharter
m(1)(9)(10), velavan tp(4)(5), mordmüller b(1)(4)(11), kremsner pg(1)(4)(11),
adegnika aa(12)(13)(14)(15).

author information: 
(1)centre de recherches médicales de lambaréné, bp: 242, lambaréné, gabon.
(2)department parasitology, leiden university medical center, leiden, the
netherlands.
(3)center tropical medicine travel medicine, department infectious
diseases, amsterdam university medical centers, university amsterdam,
amsterdam, netherlands.
(4)institut für tropenmedizin, universität tübingen, tübingen, germany.
(5)vietnamese-german center medical research, hanoi, vietnam.
(6)division infectious diseases tropical medicine, department medicine 
1, medical university vienna, vienna, austria.
(7)programme national de lutte contre le paludisme, libreville, gabon.
(8)hôpital albert schweitzer de lambaréné, lambaréné, gabon.
(9)department tropical medicine, bernhard nocht institute tropical
medicine, hamburg, germany.
(10)department medicine, university medical center hamburg-eppendorf, hamburg,
germany.
(11)german center infection research, tübingen, germany.
(12)centre de recherches médicales de lambaréné, bp: 242, lambaréné, gabon.
aadegnika@cermel.org.
(13)institut für tropenmedizin, universität tübingen, tübingen, germany.
aadegnika@cermel.org.
(14)department parasitology, leiden university medical center, leiden, the
netherlands. aadegnika@cermel.org.
(15)german center infection research, tübingen, germany.
aadegnika@cermel.org.

background: malaria remains major public health problem, affecting mainly
low-and middle-income countries. management parasitic disease is
challenged ever increasing drug resistance. study, investigated the
therapeutic efficacy, tolerability safety artemether-lumefantrine (al) and
artesunate-amodiaquine (as-aq), used first-line drugs treat uncomplicated
malaria lambaréné, gabon.
methods: non-randomized clinical trial conducted october 2017 and
march 2018 assess safety, clinical parasitological efficacy fixed-doses
of al as-aq administered treat uncomplicated plasmodium falciparum malaria
in children aged 6 months 12 years. 50 children treated with
al, another 50 children received asaq. 2009 world health organization
protocol monitoring efficacy anti‑malarial drugs followed.
molecular markers msp1 msp2 used differentiate recrudescence and
reinfection. investigation artemisinin resistant markers, gene
mutations pfk13 screened.
results: per-protocol analysis day 28 showed pcr corrected cure rate 97% 
(95% ci 86-100) 95% (95% ci 84-99) al as-aq, respectively. most
frequent adverse event groups asthenia. mutations kelch-13 
gene associated artemisinin resistance identified. participants had
completed microscopic parasite clearance day 3 post-treatment.
conclusion: study showed al as-aq remain efficacious,
well-tolerated, safe treat uncomplicated malaria children from
lambaréné. however, regular monitoring efficacy study molecular
markers drug resistance artemisinin field isolates essential. trial
registration anzctr, actrn12616001600437. registered 18 november,
http://www.anzctr.org.au/trialsearch.aspx?searchtxt=actrn12616001600437p&isbasic=
true.

doi: 10.1186/s12936-019-3015-4 
pmcid: pmc6916217
pmid: 31842893  [indexed medline]

